Premium
Private equity investors as well as pharmaceutical companies are showing higher interest in the bulk-drugs segment in India, industry executives say, as a disruption in global supplies from China opens up more growth opportunities. China is one of the biggest global suppliers of active pharmaceutical ingredients (API), or bulk drugs used ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
